

PanGenomic Health Announces Stock Option Grants

Vancouver, British Columbia, Canada, December 5, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that its Board of Directors has granted stock options representing a total of 2,00,000 common shares to officers and directors of the Company and its subsidiaries. These options were granted at an exercise price of \$0.65, being the closing price on December 4, 2025, will vest in equal quarterly instalments over a one year period, and will expire on December 5, 2028. All options were granted pursuant to the Company's Stock Option Plan.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For more information, please contact:

Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 305 5369
fair@fairfax.partners

This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedarplus.ca.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.